CannabisLink.ca - Top Stories

Top Stories (2026) - (1524 items)

(All links open in new tab)

Sep 15, 2026	Vermont Lt. Gov. Settles with Regulators for Cultivating Cannabis Plants at Unlicensed Location Vermont Lt. Gov. John Rodgers (R) says he agreed to pay a $2,500 fine to state regulators to settle a violation for growing about 200 cannabis plants at an unlicensed location, Vermont Public reports. The settlement cuts the initial $5,000 fine in half. In an interview with Vermont Public, Rodgers called the fine “very expensive… for a very minor infraction that could have been dealt with in a much easier collegial way.” He explained that his son, a partner in the cannabis businesses, neglected to tell the Cannabis Control Board (CCB) about the greenhouse in West Glover. “Sometimes you drop the ball and it’s on me. I dropped the ball because after my son put the application in, I didn’t check to make sure.” — Rogers to Vermont Public
Sep 15, 2026	What Is Going On With French Medical Cannabis Regulations? In late June 2026, an official decree on how France will govern the reimbursement of medical cannabis was reportedly submitted to the French Council of State, as the Union of Manufacturers for the Utilization of Hemp Extracts (UIVEC) announced at the time. “On 30 June, Laurent Panifous, Minister Delegate for Relations with Parliament, confirmed that the decree on the rules for the coverage of cannabis-based medicines, finalised in mid-June, had received the Ministry of Economy’s approval. This text, which is essential for the transition to a permanent framework, will be sent to the Council of State today for examination after the summer break and publication to be announced at the beginning of the school year.” UIVEC wrote on LinkedIn, translated from French to English.
Sep 15, 2026	Medical cannabis may improve endometriosis symptoms – study Women with endometriosis reported less pain and better sleep after taking medical cannabis, with improvements lasting for two years in a UK study. Researchers cautioned that the findings do not prove medical cannabis caused the improvements because the study had no control group and participants received different products and doses. The observational study followed 101 women prescribed cannabis-based medicines and also recorded improvements in anxiety, quality of life and the effect of pain on daily activities.
Sep 15, 2026	Inside Northern Leaf’s Remarkable Turnaround: From Brink of Collapse to £8m Cultivator Northern Leaf, the Jersey-based medical cannabis cultivator, looked all but certain to follow in the footsteps of Curaleaf, Aurora and Tilray to become the British Isles’ very own international cannabis superstar. In 2021, the height of the global ‘green rush’, Northern Leaf was granted the first British high-THC commercial cultivation licence since GW Pharmaceuticals (now Jazz Pharmaceuticals) in 1998.
Sep 14, 2026	How Canadian Cannabis Producers Learned to Make Money For the last few years, the story of many of Canada’s LPs has felt more like an episode of Survivor than an upward growth trend. Companies closed facilities, cut staff, restructured operations, and the catalysts for needing those changes will forever be debated in the history books. That reality, however, seems to be changing as more Canadian producers report stronger margins and sustained profitability. But the companies emerging from the industry’s prolonged shakeout look considerably different from the LPs that raced to build capacity following legalization.
Sep 14, 2026	Portugal’s Regulator Defends Cannabis Crackdown as Export Permit Delays Fall Portugal’s medicines regulator has defended a year of tightened oversight and extended licensing delays throughout the country’s medical cannabis sector, telling operators that export certificates are now issued within 12 days and that the enforcement which unsettled the market stemmed from record-keeping and traceability failures rather than problems with the product itself. Speaking at the Portugal Medical Cannabis (PTMC) conference in Lisbon yesterday (September 10, 2026) Vasco Bettencourt, Director of the Licensing Unit within Infarmed’s Inspection and Licensing Directorate, said the regulator had strengthened supervision of traceability, waste management and the qualification of customers and suppliers after weaknesses in those areas triggered criminal investigations. The problem, he said, lay in paperwork and partner checks, not in the medicines themselves. Portugal is Europe’s largest medical cannabis exporter, but the enforcement drive and the permit backlog that followed is forcing many supply chains to reroute elsewhere, threatening the country’s long held reputation as the ‘doorway’ to European cannabis markets.
Sep 14, 2026	Aurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The Facts EDMONTON, AB, Sept. 14, 2026 /CNW/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, today responded to the application by Curaleaf Holdings, Inc. ("Curaleaf") (TSX: CURA) (OTCQX: CURLF) to halt Aurora's at-the-market ("ATM") program. Aurora believes Curaleaf's filing is simply the latest attempt to distract shareholders from the fundamental issue before them: Curaleaf's hostile bid significantly undervalues Aurora and seeks to acquire Aurora's cash, unique EU-GMP assets, global growth platform and future upside at a discount.
Sep 14, 2026	Indigenous cannabis shop owners fight Ottawa closures The email came one day in May, 2025. Bryan Brant’s landlord said the police had contacted him about his cannabis dispensary and that Brant was being evicted. He had 48 hours to vacate his shop — Native Cannabis Depot — on Bank Street. Brant, as an Indigenous businessperson, claimed he had rights to open and run such an unlicensed shop. But the closure became just one of several in Ottawa that he and another Indigenous owner have been fighting.
Sep 14, 2026	Curaleaf asks Alberta regulator to halt Aurora's share issuances while its offer stands Curaleaf has filed an application with the Alberta Securities Commission seeking to stop Aurora Cannabis from issuing shares under its at-the-market program for as long as Curaleaf's offer for the company remains outstanding. The application asks the commission to halt further issuances immediately and to protect the ability of Aurora shareholders to consider and respond to the offer, and Curaleaf has requested an expedited hearing. It follows Curaleaf's formal offer for all issued and outstanding Aurora shares, commenced on 19 August at 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash per Aurora share, which the company values at approximately US$4.00, and Aurora's rejection of it.
Sep 14, 2026	Report: Cannabis Excise Taxes Totaled Over $3.5 Billion Across 30 U.S. States Last Year Locally licensed cannabis retailers in 30 U.S. states and the District of Columbia generated about $3.55 billion in cannabis excise tax revenues between July 2025 and June 2026, according to a U.S. Census report.
Sep 14, 2026	Cayman Islands Considers Cannabis Reform Options Government officials in the Cayman Islands, a self-governing British Overseas Territory located in the western Caribbean Sea, are reviewing public responses regarding proposed changes to current cannabis laws. The public submitted responses during a two-month consultation period. On July 1st, 2026, the Cayman Islands government published its “Cannabis Reform: Options for a Harm Minimisation Framework” discussion paper, which included various options to consider for modernizing current cannabis laws. The public consultation period ended on September 1st.
Sep 14, 2026	Bill Directing Federal Health Officials To Track Testing For Marijuana And Other Drugs In Hospital ERs Set For House Vote This Week The U.S. House of Representatives is expected to vote on a bill this week to require the Department of Health and Human Services (HHS) to study how prevalent drug testing for marijuana, fentanyl and other drugs is in hospital emergency departments.
Sep 14, 2026	Cannabis: do workplaces have a problem with ‘drug thinking’? A laboratory can answer the wrong question perfectly. An employee provides a sample. The result is positive for cannabis. The analysis may be technically sound, the chain of custody secure and the paperwork satisfyingly complete. But what, exactly, has the test shown? That has become harder to answer since 2018, when certain cannabis-based products for medicinal use were moved into Schedule 2 of the Misuse of Drugs Regulations, creating a lawful route to prescription. Recreational cannabis did not become legal. Yet cannabis can now sit, depending on context, on both sides of a workplace ‘drug’ policy: prescribed medicine and illicit drug. The Care Quality Commission reported a 130% rise in private prescription items for unlicensed cannabis-based medicinal products between 2022-23 and 2023-24. Those are prescription items, not patients, but the rise makes medical cannabis increasingly difficult for employers to regard as marginal.
Sep 12, 2026	Can Exercise Get You High? The Surprising Link Between Cannabis and Exercise The research over the last decade has been diving deeper into cannabis use and its effects on the body and mind. Some studies have even found surprising correlations between the euphoric feeling during exercise—sometimes referred to as a runner’s high—and how your body reacts to cannabis. That high can feel like a change in mood to straight up euphoria. And as it turns out, it is the result of activation of the endocannabinoid system—cannabis-like substances that our bodies produce naturally.
Sep 11, 2026	What Massachusetts Cannabis Consumers Need to Know About Question 8, The Ballot Measure To Roll Back Legalization (Op-Ed) If you are a Massachusetts voter who has not been following the debate over cannabis policy, Question 8 on this November’s ballot deserves your attention. The measure asks voters whether Massachusetts should repeal the laws that allow and regulate adult-use cannabis sales. The implications go well beyond whether a dispensary remains open. The question reaches the system of licensed businesses, product testing, taxation and regulatory oversight that Massachusetts has built over the past decade—seeking to eliminate 27,000 jobs and $300,000,000 in tax revenue that will need to be made up somewhere else.
Sep 11, 2026	Positive Early Results for Dutch Cannabis Supply Chain Pilot The Netherlands’ experiment to introduce regulated cannabis into its coffeeshop system is going well, despite some growing pains, according to the first follow-up study after the program launched in 2025. The Dutch Government launched its Controlled Cannabis Supply Chain Experiment in April 2025, as part of a plan for a “closed cannabis chain” for dozens of cannabis coffeeshops in ten cities across the country. The experiment is planned to continue through the end of 2029, with the goal of better understanding how to fully regulate cannabis sold in the Netherlands.
Sep 11, 2026	Mexico’s Supreme Court allows home cannabis edibles, but with a limited practical effect Mexico’s Supreme Court has ruled that people with personal recreational cannabis authorizations can now make marijuana-infused edibles for their own personal use — but people still cannot legally buy or sell them. The ruling — which applies to gummies, brownies and other homemade edibles laced with cannabis — expands what the Federal Commission for Protection against Sanitary Risks (Cofepris) must allow under an authorization for adult recreational self-consumption.
Sep 11, 2026	What Curaleaf’s hostile takeover bid for Aurora Cannabis is really about First, this is not a $4 cash offer. Aurora shareholders would receive $0.75 in cash and 0.3463 Curaleaf subordinate voting shares for each Aurora share. When Curaleaf announced the bid, that package was worth approximately $4. But its value changes with Curaleaf’s stock price, which during trading Thursday afternoon was hovering around $10.09 per share on over-the-counter markets. Despite announcing intentions to uplist to a major exchange in May, Curaleaf remains listed on OTC. If Curaleaf’s stock falls, Aurora shareholders receive less. If Curaleaf’s stock rises far enough, the exchange ratio is reduced so that the total consideration does not exceed $5 per share. Aurora shareholders are exposed to the decline, but their upside stops at $5. The cash portion deserves a closer look.
Sep 10, 2026	Avicanna Launches New Integrated Health Program to Expand Medical Cannabis in Clinical Settings Medical cannabis company Avicanna Inc. has launched a new program to support healthcare organizations looking to incorporate medical cannabis into their existing models of care. The Toronto-based company is expanding its MyMedi.ca platform as part of its new Integrated Health Program, designed to integrate medical cannabis care and patient support into Canadian healthcare institutions and clinical networks. The new program builds on Avicanna’s existing MyMedi.ca platform, a medical cannabis care infrastructure to better serve medical cannabis patients’ needs.
Sep 10, 2026	Nebraska Supreme Court Reaffirms Validity of State’s Medical Marijuana Laws Nebraska’s highest court has upheld a pair of voter-endorsed medical marijuana measures, dismissing a legal effort that argued that fraud tainted the petition campaign that placed them before voters in 2024. In a unanimous 7-0 ruling, Jeffrey Funke, the Chief Justice, said a Lancaster County judge was correct to conclude that supporters had gathered sufficient valid signatures. The 49-page decision rejected claims brought by John Kuehn, a former senator in the state and a vocal critic of medical cannabis, along with arguments advanced by state AG Mike Hilgers and Bob Evnen, the Secretary of State.

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77